Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Garrett-Engele, Carrie M
Manns, Michael P
Porter, Peggy L
Roberts, James M
Malek, Nisar P
MetadataShow full item record
AbstractDecreased expression of the CDK inhibitor p27kip1 in human tumors directly correlates with increased resistance to chemotherapies, increased rates of metastasis, and an overall increased rate of patient mortality. It is thought that decreased p27 expression in tumors is caused by increased proteasomal turnover, in particular activation of the pathway governed by the SCFskp2 E3 ubiquitin protein ligase. We have directly tested the importance of the SCFskp-mediated degradation of p27 in tumorigenesis by analyzing the tumor susceptibility of mice that express a form of p27 that cannot be ubiquitinated and degraded by this pathway (p27T187A). In mouse models of both lung and colon cancer down-regulation of p27 promotes tumorigenesis. However, we found that preventing p27 degradation by the SCFskp2 pathway had no impact on tumor incidence or overall survival in either tumor model. Our study unveiled a previously unrecognized role for the control of p27 mRNA abundance in the development of non-small cell lung cancers. In the colon cancer model, the frequency of intestinal adenomas was similarly unaffected by the p27T187A mutation, but, unexpectedly, we found that it inhibited progression of intestinal adenomas to carcinomas. These studies may guide the choice of clinical settings in which pharmacologic inhibitors of the Skp2 pathway might be of therapeutic value.
CitationTesting the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. 2006, 103 (38):14009-14 Proc. Natl. Acad. Sci. U.S.A.
AffiliationDepartment of Gastroenterology, Hepatology, and Endocrinology, Institute for Molecular Biology, Department of Hematology and Oncology, Institute for Pathology, Hannover Medical School, D-30625 Hannover, Germany.
- Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia.
- Authors: Auld CA, Fernandes KM, Morrison RF
- Issue date: 2007 Apr
- Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
- Authors: Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS
- Issue date: 2008 May 1
- STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.
- Authors: Wang S, Raven JF, Koromilas AE
- Issue date: 2010 May
- Skp2 inversely correlates with p27 and tuberin in transformed cells.
- Authors: Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschläger M
- Issue date: 2009 Jul
- [The degradation of p27 and cancer].
- Authors: Kotoshiba S, Nakayama K
- Issue date: 2005 Nov